K Rajender Reddy
Affiliation: University of Pennsylvania
- Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis CK Rajender Reddy
University of Pennsylvania, Philadelphia, PA, USA
Clin Trials 9:102-12. 2012..However, the safety and efficacy of silymarin have not been studied systematically in chronic hepatitis C...
- Response-guided and -unguided treatment of chronic hepatitis CK Rajender Reddy
Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia 19104, USA
Liver Int 32:64-73. 2012..The proper identification of those who might benefit from extended duration HCV therapy will undoubtedly lead to optimal care and outcomes...
- Ribavirin: current role in the optimal clinical management of chronic hepatitis CK Rajender Reddy
GI Division, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA 19104, USA
J Hepatol 50:402-11. 2009..Despite these recent advances in our knowledge, many questions remain, such as whether the role of ribavirin will change or even be eliminated as new therapies are developed...
- Hepatitis C virus. PrefaceK Rajender Reddy
Department of Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Liver Dis 12:xiii-xiv. 2008
- Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirinK R Reddy
GI Division, University of Pennsylvania, Philadelphia, PA 19104, USA
J Viral Hepat 15:129-36. 2008..Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance...
- Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis CK Rajender Reddy
Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Adv Drug Deliv Rev 54:571-86. 2002..Peginterferon alfa-2a (40 KD) has comparable safety to interferon alfa-2a. The addition of ribavirin to peginterferon alfa-2a (40 KD) further enhances the therapeutic benefit for patients with hepatitis C...
- Coagulopathy in liver diseaseWojciech Blonski
K Rajender Reddy, MD Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Dulles, Philadelphia, PA 19104, USA
Curr Treat Options Gastroenterol 10:464-73. 2007..Liver transplantation completely restores impaired coagulation abnormalities and is the ultimate intervention that corrects coagulopathy of advanced liver disease and liver failure...
- Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)K Rajender Reddy
Gastrointestinal Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Semin Liver Dis 24:33-8. 2004..The much-increased sustained virological response rates observed with pegylated IFN alfa-2a (40 kD) and pegylated IFN alfa-2b (12 kD) support the rationale for pegylation of IFN...
- Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatmentK Rajender Reddy
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Gastroenterol Hepatol 5:124-9. 2007..We evaluated the effects of ribavirin and peginterferon alfa-2a dose reductions on SVR in patients infected with HCV genotype 1...
- Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patientsK R Reddy
Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
J Viral Hepat 16:724-31. 2009..More frequent dose modifications of ribavirin in those >50 years likely contributed to the observed higher relapse rates...
- Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loadsK Rajender Reddy
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Gastroenterology 139:1972-83. 2010..We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin...
- Transplantation: impact of pretransplant renal insufficiencyRanjeeta Bahirwani
Division of Hepatology, University of Pennsylvania Health System, Philadelphia, PA 19010, USA
Liver Transpl 14:665-71. 2008..In conclusion, few patients with preexisting renal dysfunction, especially if <12 weeks duration, experience a significant drop in eGFR post-OLTa...
- Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trialMichael W Fried
UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
JAMA 308:274-82. 2012..The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy...
- Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver diseaseRolland C Dickson
Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
Liver Transpl 12:124-33. 2006..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT...
- Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidatesMical S Campbell
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Dig Dis Sci 52:2501-7. 2007..Kidney transplantation alone may be considered in patients with hepatitis C with compensated cirrhosis or bridging fibrosis...
- Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantationNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
Liver Transpl 13:122-9. 2007..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
- T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis CDavid E Kaplan
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
Hepatology 41:1365-75. 2005..The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance...
- Racial difference in mortality among U.S. veterans with HCV/HIV coinfectionNathan A Merriman
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Am J Gastroenterol 101:760-7. 2006..Furthermore, we demonstrated a racial disparity in survival of HCV/HIV-coinfected patients that needs further investigation...
- Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevationMical S Campbell
Division of Gastroenterology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
Liver Transpl 11:1048-55. 2005..01) after transplantation. In conclusion, duration, but not cause, of renal dysfunction predicts renal outcome in OLTa recipients. Prospective studies may use duration of renal dysfunction to help identify CKLT candidates...
- Recurrence of diseases following orthotopic liver transplantationDavid S Kotlyar
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Am J Gastroenterol 101:1370-8. 2006..Expert clinical management may help prevent and treat complications associated with disease recurrence...
- Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease eraDavid Goldberg
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Liver Transpl 17:1355-63. 2011....
- Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis CDavid E Kaplan
Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Gastroenterology 132:654-66. 2007..Although HCV-specific CD4 T-cell response is associated with HCV clearance, less is known about virus-specific CD8 T-cell or neutralizing antibody (nAb) responses and the role of CD4 help in their induction during acute infection...
- Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD eraPaige M Porrett
The University of Pennsylvania Department of Surgery, Philadelphia, PA 19103, USA
Liver Transpl 12:665-73. 2006..25%) (P > 0.1). In conclusion, viable tumor frequently persists after pre-transplant locoregional therapy, and neoadjuvant treatment does not appear to improve post-transplant outcomes in the current MELD era...
- Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapyVincent Lo Re
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 44:344-50. 2007..Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically...
- Association between model for end-stage liver disease and spontaneous bacterial peritonitisKeith L Obstein
Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Am J Gastroenterol 102:2732-6. 2007..To determine whether a greater Model for End-Stage Liver Disease (MELD) score is associated with a greater risk of spontaneous bacterial peritonitis (SBP)...
- Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infectionZina Meriden
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Clin Gastroenterol Hepatol 8:289-96, 296.e1-8. 2010..Recurrent hepatitis C with ensuing fibrosis is the leading cause of liver allograft loss. We investigated whether histologic features in early posttransplant liver biopsies could predict the rate of fibrosis progression in this population...
- Chronic kidney disease after orthotopic liver transplantation: impact of hepatitis C infectionRanjeeta Bahirwani
Division of Gastroenterology and Hepatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Transplantation 91:1245-9. 2011..Hepatitis C virus (HCV) infection has been shown to be a potential risk factor for the development of chronic kidney disease in liver transplant recipients...
- Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcomeKirti Shetty
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Liver Transpl 10:911-8. 2004..e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT...
- Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shuntThomas D Boyer
Department of Medicine, University of Arizona, Liver Research Institute, Tucson, AZ 85724, USA
J Hepatol 48:407-14. 2008..We examined the cost and cost effectiveness of distal splenorenal shunt (DSRS) and transjugular intrahepatic portosystemic shunt (TIPS) in the prevention of variceal rebleeding...
- Outcomes after liver transplantation: chronic kidney diseaseRanjeeta Bahirwani
University of Pennsylvania, Philadelphia, PA, USA
Liver Transpl 15:S70-4. 2009..It is important to identify pre-liver transplant patients at high risk for early evolution of chronic kidney disease post-transplant in order to appropriately select patients for combined liver/kidney transplantation...
- Hepatitis C virus infection and immunomodulatory therapiesKimberly A Forde
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Liver Dis 13:391-401. 2009..In this article, the authors discuss immunomodulatory therapies and clinical trials in the treatment of HCV infection...
- Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinomaStephen N Wong
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:334-42. 2007..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy...
- Current trends in living donor liver transplantation for primary sclerosing cholangitisDavid Seth Goldberg
Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA
Transplantation 91:1148-52. 2011..To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently...
- Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort StudyVincent Lo Re
Philadelphia VA Medical Center, Philadelphia, PA, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Pharmacoepidemiol Drug Saf 20:689-99. 2011..We determined the ability of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events within the Veterans Aging Cohort Study (VACS)...
- Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experienceJasmohan S Bajaj
Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA 23249, USA
Hepatology 56:2328-35. 2012..03) albumin (OR: 0.5), and second infection (OR: 4.42) as significant variables. CONCLUSION: Potentially preventable second infections are predictors of mortality independent of liver disease severity in this multicenter cirrhosis cohort...
- Pruritus in chronic cholestatic liver diseaseChalermrat Bunchorntavakul
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, USA
Clin Liver Dis 16:331-46. 2012..Experimental interventions, and the management of pruritus in certain conditions such as intrahepatic cholestasis of pregnancy and benign recurrent intrahepatic cholestasis, are also briefly reviewed...
- Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran populationBarbara A Piasecki
University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Hepatology 40:892-9. 2004..016), while HBV coinfection was positively associated with HCV clearance (unadjusted OR 5.0; 95% CI, 1.26-28.6; P =.008). In conclusion, the likelihood of spontaneous clearance of HCV may be influenced by alcohol and viral coinfections...
- Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantationScott J Weston
Department of Medicine, Oregon Health and Science University, USA
Hepatology 41:72-81. 2005..Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience. wiley.com/jpages/0270-9139/suppmat/index.html)...
- The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejectionG W Neff
Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0595, USA
Transplant Proc 37:4397-402. 2005..Our objective was to determine the diagnostic accuracy of clinical and histological parameters in liver transplant recipients with RHCV and concurrent cholestasis...
- Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomesRanjeeta Bahirwani
Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Transplantation 92:952-7. 2011..It is unclear whether patients who develop acute-on-chronic liver failure (ACLF) have poor outcomes after liver transplantation...
- Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomesDavid E Kaplan
Division of Gastroenterology and Hepatology, University of Pennsylvania School of Medicine, 3 Raydin, 3400 Spruce Street, Philadelphia, PA 19104, USA
Clin Liver Dis 7:683-714. 2003..LDLT may remain an option for high-risk patients affording tumor-free survival for some otherwise terminal patients...
- Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United StatesKimberly A Forde
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, 3 Ravdin, Philadelphia, Pennsylvania 19104, USA
Clin Gastroenterol Hepatol 7:1121-6. 2009..In patients with chronic liver disease, race plays a role in the rate of survival after transplantation. It is not known how race and ethnicity influence the presentation, etiology, and outcomes in patients with acute liver failure (ALF)...
- Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoproteinStephen A Harrison
Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
J Clin Gastroenterol 47:271-9. 2013..Our aim was to determine whether SVR rates in patients with low/elevated LDL can be improved by dose intensification...
- Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case seriesCalvin Q Pan
Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, Mount Sinai School of Medicine, New York, NY, USA
Dig Dis Sci 57:2423-9. 2012..Use of TDF to prevent vertical transmission (VT) by such mothers has not been evaluated...
- Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting listRoy D Bloom
Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Am J Transplant 5:139-44. 2005..Diabetic HCV+ kidney candidates are therefore a patient subgroup that requires frequent and careful reevaluation to ensure ongoing transplantability...
- Biologic and clinical features of benign solid and cystic lesions of the liverOren Shaked
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Clin Gastroenterol Hepatol 9:547-62.e1-4. 2011..These advances have led to constant adjustments in management approaches to benign hepatic lesions. We review the biologic and clinical features of some common hepatic lesions, to guide diagnosis and management strategies...
- Hepatitis C virus infection and hepatocellular carcinomaWojciech Blonski
Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Liver Dis 12:661-74, x. 2008..Although several studies suggested the preventive effect of interferon from developing HCC in HCV-infected individuals, these findings need to be validated in large prospective and randomized trials...
- Factors that influence the severity of recurrent hepatitis C virus following liver transplantationSteven B Porter
Department of Medicine, GI Division, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3 Ravdin, Philadelphia, PA 19104, USA
Clin Liver Dis 7:603-14. 2003..Finally, features that may influence outcomes over which there is no control include: recipient age, recipient gender, and donor age (in the case of cadaveric donors). Unfortunately, the best-case scenario is uncommon...
- Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treatedK Rajender Reddy
University of Pennsylvania, USA
Am J Gastroenterol 99:973-5. 2004
- Allograft survival following adult-to-adult living donor liver transplantationPeter L Abt
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Am J Transplant 4:1302-7. 2004..Analysis of this early experience with AALDLT suggests that allograft failure may be higher than among recipients of a cadaveric liver...
- Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver functionMichael R Lucey
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 5124, USA
Am J Gastroenterol 103:1698-706. 2008....
- Association between proton pump inhibitor use and spontaneous bacterial peritonitisMical S Campbell
Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Dig Dis Sci 53:394-8. 2008..22 (95% confidence interval: 0.52-2.87) and 1.05 (0.43-2.57), respectively. In conclusion, we did not find a positive association between PPI use and spontaneous bacterial peritonitis...
- Postoperative jaundiceThomas W Faust
Division of Gastroenterology, Department of Internal Medicine, The University of Pennsylvania School of Medicine, 3 Ravdin, 3400 Spruce Street, Philadelphia, PA 19104, USA
Clin Liver Dis 8:151-66. 2004..Treatment includes removal of offending drugs, supportive care, broad-spectrum antibiotic agents with drainage of infected fluid collections, adjustment of TPN, and either cholecystectomy or cholecystostomy, respectively...
- Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitisDavid E Kaplan
Research Section, Philadelphia VA Medical Center, Research A216, 3900 Woodland Avenue, Philadelphia, PA 19104, USA
J Hepatol 48:903-13. 2008..In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection...
- Evaluation of nonmalignant liver massesWojciech Blonski
Department of Medicine, Division of Gastroenterology, 3 Ravdin Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19014, USA
Curr Gastroenterol Rep 8:38-45. 2006..An invasive approach is seldom required. This review discusses the various characteristics of the most common benign liver lesions and recommends a practical approach...
- Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literatureWojciech C Blonski
Gastroenterology Division, University of Pennsylvania Health System, 3400 Spruce Street, 3 Ravdin Building, Philadelphia, PA 19104, USA
World J Gastroenterol 11:7676-83. 2005..We report a case of liver transplantation for metastatic neuroendocrine tumor of unknown primary source and provide a detailed review of the world literature on this controversial topic...
- Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
Pharmacoepidemiol Drug Saf 21:1202-15. 2012..To describe the design and rationale of a series of postmarketing studies to examine the safety of saxagliptin, an oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus, in real-world settings...
- Noncirrhotic portal hypertension: another cause of liver disease in HIV patientsManuel Mendizabal
Department of Gastroenterology, University of Pennsylvania, Philadelphia, USA
Ann Hepatol 8:390-5. 2009..Prolonged exposure to ART, specially ddl, can play a pathogenic role. Rarely, liver synthetic function is sufficiently severe to warrant liver transplantation...
- Portal flow and arterioportal shunting after transjugular intrahepatic portosystemic shunt creationMaxim Itkin
Section of Interventional Radiology, Department of Radiology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Vasc Interv Radiol 17:55-62. 2006..Further work is necessary to correlate Q(TIPS) with the risk of hepatic encephalopathy and liver failure...
- Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapyMical S Campbell
Division of Gastroenterology, University of Pennsylvania Health Services, Philadelphia, PA 19104, USA
Hepatology 42:635-40. 2005..Competing effects of hepatic encephalopathy, requirement for repeated LVP, and need for hospitalizations explain similar changes in quality of life between the two groups...
- Approach to a liver massOren Shaked
School of Medicine, 2 Dulles, 3400 Spruce Street, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Liver Dis 13:193-210. 2009..Various imaging modalities can be utilized to accurately diagnose such masses without resort to more invasive diagnostic measures...
- One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapyDavid D Kaplan
University of Pennsylvania, Philadelphia, USA
Am J Gastroenterol 97:2465-7. 2002
- Immune dysfunction and infections in patients with cirrhosisAlexander R Bonnel
Division of Gastroenterology Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Gastroenterol Hepatol 9:727-38. 2011..We review the pathogenesis of infections in these patients, along with diagnostic and management strategies...
- Endoscopic management of biliary complications after adult living donor liver transplantationJanak N Shah
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
Am J Gastroenterol 99:1291-5. 2004..ERCP is useful for diagnosis, can successfully treat most LDLT-related biliary complications, and should be attempted prior to more invasive interventions...
- Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinomaNoriyo Yamashiki
Division of Transplantation, Department of Surgery, University of Miami School of Medicine, Miami, FL, USA
Am J Transplant 4:774-81. 2004..001). In conclusion, the initial AFP level may be useful along with tumor stage in defining an urgency score for liver transplant candidates with HCC...
- Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried
University of North Carolina, Chapel Hill 27599, USA
N Engl J Med 347:975-82. 2002....
- Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapyShengyuan Luo
University of Maryland School of Medicine, USA
Clin Gastroenterol Hepatol 3:499-506. 2005..CONCLUSIONS: The mechanisms of resistance to PEG-IFN combination therapy may be different in black and white HCV genotype 1 patients...
- Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee
Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
J Hepatol 37:500-6. 2002..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
- First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral declineJennifer E Layden
University of Illinois at Chicago, Chicago, IL, USA
J Viral Hepat 9:340-5. 2002..This might be explained by a viral dynamics model assuming a jump-start of the immune response when viral loads are reduced below a threshold, subsequently giving rise to a faster 2nd phase decline slope...
- Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practiceMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298, USA
Am J Gastroenterol 98:1159-66. 2003..The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection...
- Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis CThomas J Layden
University of Illinois at Chicago, Chicago, IL
J Viral Hepat 9:334-9. 2002..They also suggest that early viral kinetics during the first month of therapy can predict non-SVR and thus save a patient a year long treatment which is fraught with side-effects and significant cost...
- Pegylated interferonsUmaprasanna S Karnam
Department of Gastroenterology and Hepatology, Central Utah Medical Clinic, 36 North 1100 East, American Fork, UT 84003, USA
Clin Liver Dis 7:139-48. 2003..Pegylated IFNs with ribavirin are the standard of care for treating patients with chronic HCV who have not been treated previously...
- Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1Lennox J Jeffers
Miami Veterans Affairs Medical Center, Miami, FL, USA
Hepatology 39:1702-8. 2004....
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinPeter Ferenci
Medical University of Vienna, Vienna, Austria
J Hepatol 43:425-33. 2005..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
- Management of hepatitis C virus in special populations: patient and treatment considerationsRobert G Gish
Liver Transplant Program and Division of Hepatology and Complex GI, California Pacific Medical Center, 2340 Clay Street 232, San Francisco, CA 94115, USA
Clin Gastroenterol Hepatol 3:311-8. 2005..Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy...
- Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosisPaul J Pockros
Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
Hepatology 45:569-78. 2007..Subgroups of patients with elevated ITAC levels and perhaps less advanced disease may be considered for future studies with IFN-gamma1b...
- Strategies for managing anemia in hepatitis C patients undergoing antiviral therapyJohn G McHutchison
Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
Am J Gastroenterol 102:880-9. 2007..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
- Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirinMaria H Sjogren
Walter Reed Army Medical Center, Washington, DC 20307, USA
Dig Dis Sci 52:1540-7. 2007..It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1...
- Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosisRichard K Sterling
Virginia Commonwealth University Health Systems, Richmond, Virginia, USA
Am J Gastroenterol 102:2196-205. 2007..The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients...
- Hepatitis C virus-infected donors in liver transplantationRichard Peek
Gastroenterology 133:381-2. 2007
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapyDonald M Jensen
Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
Hepatology 43:954-60. 2006..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
- Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem
Saarland University Hospital, Homburg Saar, Germany
Gastroenterology 127:1724-32. 2004....
- Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2aPatrick Marcellin
Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
Liver Int 28:477-85. 2008..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
- Rapid virologic response: a new milestone in the management of chronic hepatitis CFred Poordad
Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Infect Dis 46:78-84. 2008..This assessment is being used to individualize treatment duration, which is currently recommended as 48 weeks in patients infected with HCV genotype 1 (G1) and 24 weeks in those infected with HCV G2 or G3...
- Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis CKirti Shetty
Division of Transplantation, Georgetown University Hospital, Washington, DC 20007, USA
Liver Transpl 14:534-40. 2008..Occult HBV infection is strongly associated with the presence of anti-HBc, history of injection drug use, and explant-proven HCC...
- Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros
Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California 92037, USA
Am J Gastroenterol 99:1298-305. 2004..A significantly higher proportion of patients treated with the 180 microg dose of peginterferon alpha-2a had clinically significant histological improvement...
- Ribavirin considerations in treatment optimizationGeoffrey Dusheiko
Royal Free Hospital, London, United Kingdom
Antivir Ther 13:23-30. 2008..Here, we discuss how optimizing the ribavirin component of combined therapy for HCV is an essential part of treatment optimization...
- Diagnosis and treatment of hepatocellular carcinomaHashem B El-Serag
Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas 77030, USA
Gastroenterology 134:1752-63. 2008..In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach...
- First, do no harm: The question of liver biopsy in living liver donorsKim M Olthoff
Liver Transpl 14:420-2. 2008
- Laparoscopic observations of the liver in hereditary hemorrhagic telangiectasiaWojciech Blonski
Scand J Gastroenterol 42:1512-3. 2007
- Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudineJose R Nery
University of Miami School of Medicine, Department of Surgery, Division of Liver GI Transplantation, Miami, FL, USA
Transplantation 75:1179-86. 2003..We reviewed our experience with liver grafts from hepatitis-B surface antigen (HBsAg)(-), antibody to core antigen (anti-HBc)(+) donors...
- Doctor Griffin Rodgers at helm of the National Institute of Diabetes and Digestive and Kidney DiseasesRichard Peek
Gastroenterology 133:380-1. 2007
- Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infectionArie Regev
Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, Florida 33136, USA
Am J Gastroenterol 97:2614-8. 2002..A sampling error may have led to underdiagnosis of cirrhosis in 14.5% of the patients. These differences could not be attributed to intraobserver variation, which appeared to be low...
- The North American Study for the Treatment of Refractory AscitesArun J Sanyal
Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA
Gastroenterology 124:634-41. 2003..The clinical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-à-vis total paracentesis in the management of refractory ascites is unclear...
- A phase I/II trial of silymarin for chronic liver diseasesRajender Reddy; Fiscal Year: 2007..This study will examine the safety and tolerability of various doses of milk thistle as well as start to explore its role in hepatitis C. ..